October 28th 2020, 12:44pm
Evolution and collaboration are the fundamentals of bringing oncology payment reform plans to fruition, say 3 professionals on the front lines.
October 28th 2020, 12:00pm
During a session on day 1 of the Community Oncology Alliance (COA) Virtual Payer Exchange Summit on Oncology Payment Reform, a panel of experts discussed the ways COVID-19 continues to impact cancer care and payment reform.
October 25th 2020, 11:00am
Andre Goy, MD, chairman, director, and chief of the Division of Lymphoma at John Theurer Cancer Center in Hackensack, NJ, discussed the potential benefits of using CAR T-cell therapies as a second-line treatment.
October 23rd 2020, 8:35pm
In her presentation, Aimee Tharaldson, PhD, senior clinical pharmacist of emerging therapeutics at Express Scripts, discussed the upcoming pipeline of specialty drug approvals and their potential impact on the market.
October 22nd 2020, 9:00pm
Experts in cancer care and payment discussed the future of oncology care in a panel discussion hosted by Avalere Health on October 21, 2020.
October 21st 2020, 5:00pm
At Dana Farber Cancer Institute, essential steps to developing clinical pathways include engaging physicians to buy-in, finding the optimal platform to store data, and displaying resulting content in a supportive and efficient way.
October 16th 2020, 1:15pm
A study and accompanying editorial from the Journal of Clinical Oncology found that Hodgkin lymphoma survivors still face a higher risk of non-cancer death than the general population.
October 11th 2020, 12:00pm
Distance caregivers have unique needs, explained Sara L. Douglas, PhD, RN, the Gertrude Perkins Oliva Professor in Oncology Nursing, associate dean for research, the Frances Payne Bolton School of Nursing, Case Western Reserve University.
October 10th 2020, 2:00pm
Natera’s Signatera ctDNA test will determine study eligibility and treatment effectiveness in HR-positive, HER2-negative breast cancer patients.
October 4th 2020, 12:00pm
Addressing gaps in testing and education within precision oncology can assist in improving access to patients of color and other underserved populations.
